24 A molecular signature based on ifn gene signature and serology defines two populations of patients with different baseline disease activity

Autor: David A. Isenberg, Matthew D. Linnik, Richard E. Higgs, Steven Watts, Murray B. Urowitz, M Morgan-Cox, Kenneth C. Kalunian, Richard Furie, M. Petri, M. Silk, Ernst R. Dow

Publikováno v: Parallel Session 8: Innate immunity and interferon.

Background and Aims Randomised controlled trials in SLE have shown that response to treatment is influenced by baseline disease activity. The current investigation used objective molecular and biochemical baseline parameters to characterise SLE patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d87acd73c50cc6fc07bf300f5ac1657f
https://doi.org/10.1136/lupus-2017-000215.24

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Autor: P-Y Berclaz, Jill P. Buyon, M Morgan-Cox, Joan T. Merrill, William Stohl, Pamela W. Anderson, Chin Lee, C. Dickson, Richard Furie, Thomas Dörner, R. van Vollenhoven

Publikováno v: Annals of the Rheumatic Diseases, 75(2), 332-40. BMJ Publishing Group
Merrill, J T, van Vollenhoven, R F, Buyon, J P, Furie, R A, Stohl, W, Morgan-Cox, M, Dickson, R C, Anderson, P W, Lee, C, Berclaz, P-Y & Dörner, T 2016, ' Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus : results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study ', Annals of the Rheumatic Diseases, vol. 75, no. 2, pp. 332-40 . https://doi.org/10.1136/annrheumdis-2015-207654

OBJECTIVES: To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that neutralises membrane and soluble B-cell activating factor (BAFF).METHODS: This randomised, placebo-controlled study enrolled 1124 patients with modera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5fc4bc66603c574c6d26b02e2bb4ecb
https://research.vumc.nl/en/publications/7aceda4c-dd8b-4a0a-bd3c-114c0b667586

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.